NEW YORK, NY / ACCESSWIRE / October 6, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
SFIX Shareholders Click Here: https://www.zlk.com/pslra-1/stitch-fix-class-action-loss-submission-form?prid=32475&wire=1
ABT Shareholders Click Here: https://www.zlk.com/pslra-1/abbott-laboratories-class-action-lawsuit-submission-form?prid=32475&wire=1
YSG Shareholders Click Here: https://www.zlk.com/pslra-1/yatsen-holding-loss-submission-form?prid=32475&wire=1
* ADDITIONAL INFORMATION BELOW *
Stitch Fix, Inc. (NASDAQ:SFIX)
This lawsuit is on behalf of purchasers of Stitch Fix Class A common stock between December 8, 2020, and March 8, 2022, inclusive.
Lead Plaintiff Deadline : October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/stitch-fix-class-action-loss-submission-form?prid=32475&wire=1
According to the filed complaint, Stitch Fix made numerous false and misleading statements to investors concerning the synergy between the Company's Fix and Freestyle programs, and repeatedly denied claims that the Freestyle program could cannibalize the Company's legacy Fix business. Specifically, Stitch Fix repeatedly assured investors that the Company's Freestyle business was "an additive experience" and "complementary" to the Fix business, that "the combination of those two things will allow us to address many more types of clients," and that "we see solid growth in both sides of the business." In truth, Stitch Fix concealed that these programs were not complementary or additive. Stitch Fix knew that the Freestyle program would be much preferred to the Company's original Fix model and that the Freestyle program would inevitably cannibalize the Company's legacy Fix business.
Abbott Laboratories (NYSE:ABT)
This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.
Lead Plaintiff Deadline : October 31, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbott-laboratories-class-action-lawsuit-submission-form?prid=32475&wire=1
According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ("FDA") health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.
Yatsen Holding Limited (NYSE:YSG)
This lawsuit is on behalf of a class consisting of all persons and entities who purchased Yatsen Holding Limited American Depository Shares ("ADS") between November 19, 2020 and March 10, 2022 or acquired Yatsen ADS pursuant or traceable to documents issued in connection with Yatsen's November 2020 initial public stock offering.
Lead Plaintiff Deadline : November 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/yatsen-holding-loss-submission-form?prid=32475&wire=1
According to the filed complaint, the registration statement and prospectus used to effectuate the Company's initial public offering ("IPO"), Yatsen and the other named defendants misled investors into believing that Yatsen's most significant brands, Perfect Diary and Little Ondine, were thriving, thereby driving Yatsen's "healthy" top-line growth at the time of its IPO and quarter after quarter thereafter. In truth, however, cosmetic and skincare sales of Perfect Diary and Little Ondine products were declining in the period leading up to (and including at the time of) the IPO and throughout 2021. Moreover, as the truth about Yatsen's business reached the market, the value of the Company's shares declined dramatically, causing Yatsen investors to suffer significant damages.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP